Clinical and Translational Oncology

, Volume 15, Issue 10, pp 780–788 | Cite as

Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences

  • Jun Ren
  • Lijun Di
  • Guohong Song
  • Jing Yu
  • Jun Jia
  • Yuling Zhu
  • Ying Yan
  • Hanfang Jiang
  • Xu Liang
  • Li Che
  • Jie Zhang
  • Fengling Wan
  • Xiaoli Wang
  • Xinna Zhou
  • Herbert Kim Lyerly
Research Article

Abstract

Background

We hypothesized that combination of dendritic cell (DC) with autologous cytokine-induced killer (CIK) immunotherapy in setting of high-dose chemotherapy (HDC) would be effective for selected metastatic breast cancer (MBC) patients.

Patients and methods

Our previous work showed thiotepa could eradicate breast cancer stem cells. From 2004 to 2009, 79 patients received standard dose chemotherapy (SDC) of 75 mg/m2 docetaxel and 75 mg/m2 thiotepa versus 87 patients of HDC + DC/CIK: 120 mg/m2 docetaxel to mobilize peripheral CD34+ progenitor cells, a sequence of HDC (120 mg/m2 docetaxel, plus 175 mg/m2 thiotepa) + DC/CIK, with or without 400 mg/m2 carboplatin depending upon bone marrow function. The endpoints were response rates (RR), progression-free survival (PFS), and overall survival (OS).

Results

Compared with SDC, PFS and OS were improved in HDC + DC/CIK (median PFS 10.2 vs. 3.7 months, P < 0.001; median OS 33.1 vs. 15.2 months, P < 0.001). Patients of pre-menopausal, HDC as first-line treatment after metastasis, or with visceral metastasis showed prolonged PFS and OS. SDC group also achieved the similar response as previous reports.

Conclusion

Our study demonstrated the novel combination of HDC with DC/CIK to be an effective choice for the selected MBC population, in which choosing appropriate chemo regimens played important roles, and also specific HDC regimen plus DC/CIK immunotherapy showed the clinical benefits compared with chemotherapy alone.

Keywords

Metastatic breast cancer High-dose chemotherapy Immunotherapy Dendritic cells Cytokine-induced killers 

References

  1. 1.
    Higgins MJ, Wolff AC (2008) Therapeutic options in the management of metastatic breast cancer. Oncology 22:614–623PubMedGoogle Scholar
  2. 2.
    Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988PubMedCrossRefGoogle Scholar
  3. 3.
    Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275–284PubMedCrossRefGoogle Scholar
  4. 4.
    Morrison BJ, Schmidt CW, Lakhani SR et al (2008) Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res 10:210PubMedCrossRefGoogle Scholar
  5. 5.
    Hortobagyi GN, Spanos W, Montague ED et al (1983) Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy. Int J Radiat Oncol Biol Phys 9:643–650PubMedCrossRefGoogle Scholar
  6. 6.
    Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 365:411–422CrossRefGoogle Scholar
  7. 7.
    Liu PY, Chen LB, Huang X (2009) The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. Cancer Biother Radiopharm 24:91–98PubMedCrossRefGoogle Scholar
  8. 8.
    Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439PubMedCrossRefGoogle Scholar
  9. 9.
    Lu ZH, Jia J, Di LJ et al (2011) DNA methyltransferase inhibitor CDA-2 synergizes with high-dose thiotepa and paclitaxel in killing breast cancer stem cells. Front Biosci 1:240–249CrossRefGoogle Scholar
  10. 10.
    Yu J, Di LJ, Song GH et al (2011) Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer. Beijing Da XueXue Bao 43(1):151–156Google Scholar
  11. 11.
    Berry DA, Ueno NT, Johnson MM et al (2011) High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 29(24):3214–3223PubMedCrossRefGoogle Scholar
  12. 12.
    Berry DA, Ueno NT, Johnson MM et al (2011) High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol 29(24):3224–3231PubMedCrossRefGoogle Scholar
  13. 13.
    Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy—a practical partnership. Nat Rev Cancer 5:397–405PubMedCrossRefGoogle Scholar
  14. 14.
    Crump M, Gluck S, Tu D et al (2008) Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol 26:37–43PubMedCrossRefGoogle Scholar
  15. 15.
    Biron P, Durand M, Roché H et al (2008) Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transplant 41:555–562PubMedCrossRefGoogle Scholar
  16. 16.
    Demirer T, Ilhan O, Mandel NM et al (2000) A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies. Bone Marrow Transplant 25:697–703PubMedCrossRefGoogle Scholar
  17. 17.
    Kroger N, Frick M, Gluz O et al (2006) Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. J Clin Oncol 24:3919–3926PubMedCrossRefGoogle Scholar
  18. 18.
    Lotz JP, Curé H, Janvier M et al (2005) High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer 41:71–80PubMedCrossRefGoogle Scholar
  19. 19.
    Nitz UA, Mohrmann S, Fischer J et al (2005) Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 366:1935–1944PubMedCrossRefGoogle Scholar
  20. 20.
    Yu J, Ren J, Di LJ et al (2011) Mobilization of peripheral blood stem cells using regimen combining docetaxel with granulocyte colony-stimulating factor. Chin J Cancer Res 23:49–53PubMedCrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2013

Authors and Affiliations

  • Jun Ren
    • 1
    • 2
  • Lijun Di
    • 1
  • Guohong Song
    • 1
  • Jing Yu
    • 1
  • Jun Jia
    • 1
  • Yuling Zhu
    • 1
  • Ying Yan
    • 1
  • Hanfang Jiang
    • 1
  • Xu Liang
    • 1
  • Li Che
    • 1
  • Jie Zhang
    • 1
  • Fengling Wan
    • 1
  • Xiaoli Wang
    • 1
  • Xinna Zhou
    • 1
  • Herbert Kim Lyerly
    • 1
    • 3
  1. 1.Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)Peking University Cancer Hospital and InstituteBeijingChina
  2. 2.Capital Medical University Cancer CenterBeijing Shijitan HospitalBeijingChina
  3. 3.Duke University Medical CenterDurhamUSA

Personalised recommendations